Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease

Inclusion Criteria: * Patients with chronic cold agglutinin disorder requiring or with a hemoglobin concentration below 10g/L determined at least monthly during the two months before entering the trial; * Failure of at least one previous treatment attempt; * Hemoglobin level assessment; * Presence of serum cold agglutinin (CA). If an overnight incubation is used for CA detection, a titer at 4°C of 64 or higher is required; * Written informed consent. Exclusion Criteria: * Presence of a concomitant lymphoproliferative disorder requiring specific treatment for reasons other than cold agglutinin related hemolytic anemia; * Preexisting peripheral neuropathy; * Known hypersensitivity to Bortezomib; * Non-cooperative behaviour or non-compliance; * Psychiatric diseases or conditions that might impair the ability to give informed consent; * Patients who are pregnant (women of childbearing potential must have a negative serum pregnancy test). Post-menopausal women must be amenorrhoic for at least 24 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.